ALX 0171

Drug Profile

ALX 0171

Alternative Names: ALX-0171; Anti-RSV nanobody; VR 465

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator Ablynx
  • Class Antivirals; Proteins
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 23 Feb 2017 Ablynx intends to initiate clinical development for Respiratory syncytial virus infections in Japan
  • 26 Sep 2016 Ablynx initiates a phase II trial for Respiratory syncytial virus infections (In infants) in Hungary and Estonia (EudraCT2016-001651-49)
  • 01 Sep 2016 Phase-II clinical trials in Respiratory syncytial virus infections (In infants) in Germany and Lithuania (Inhalation) (EudraCT2016-001651-49)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top